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T
he advancement of nanomedicine is
currently focused on amplifying the
in vivo stability and pharmacokinetics
of formulations in an effort to enhance drug
delivery.1 However, tumor-specific abnor-
malities in the microenvironment such as
high interstitial fluid pressure (IFP) play a
critical role in hindering treatment efficacy
and can result in undesirably low drug pene-
trationwhile contributing todrug resistance.2
Specifically, tumor-associated fibroblasts
(TAFs), a primary component of the tumor
microenvironment, play a key role in defin-
ing the role and extent of tumor pro-
liferation.3 Therefore, successfully remodel-
ing the tumor microenvironment against
the conditions necessary for proliferation
may be a powerful strategy to sensitize
tumor cells to chemotherapy.48
The application of combination therapy
can be achieved through coadministration
of an additional drug alongside the sen-
sitizer.912 The interaction between two
drugs is dependent on the dose ratio be-
tween the drugs and can be synergistic or
potentially antagonistic.13,14 Therefore, the
importance of maintaining the synergistic
therapeutic ratio throughout the nanopar-
ticle (NP) formulation cannot be over-
looked. The process of coencapsulating
two drugs into a single NP proves difficult
if the drugs differ greatly in their physico-
chemical properties. Therefore, formula-
tions, which are capable of encapsulating
and delivering multiple drugs with diverse
physicochemical properties while maintain-
ing the controlled synergistic ratio, are thus
desired.
* Address correspondence to
guost@email.unc.edu,
leafh@unc.edu.
Received for review February 23, 2014
and accepted April 10, 2014.
Published online
10.1021/nn5010815
ABSTRACT The tumor microenvironment plays an important role in the tumor's
progression and metastasis. Therefore, successful alteration of this delicate setting
against the tumor's favor can open a window for therapeutic efficacy. We have developed
a modality to bring about treatment-induced alterations in the tumor microenvironment
by employing the synergistic effects between two drugs. Co-delivery of rapamycin
(RAPA), an mTOR inhibitor that may offer notable therapy through antiangiogenic
activity, alongside cisplatin can foster significant potency as RAPA sensitizes A375
melanoma cells to cisplatin therapy through microenvironment modulation. However,
encapsulation of these drugs into poly(lactic-co-glycolic acid) (PLGA) NPs was inefficient
due to the incompatibility between the two free drugs and the polymer matrix. Here, we
show cisplatin can be made hydrophobic by coating a nanoprecipitate (cores) of the drug
with dioleoylphosphatidic acid (DOPA). These DOPA coated cisplatin cores are compatible with PLGA and can be coencapsulated in PLGA NPs alongside RAPA
at a molar ratio to promote synergistic antitumor activity. The presence of the cisplatin cores significantly improved the encapsulation of RAPA into PLGA
NPs. Furthermore, PLGA NPs containing both cisplatin cores and RAPA induced significant apoptosis on A375-luc human melanoma cells in vitro.
Additionally, they inhibited the growth of A375-luc melanoma in a xenograft tumor model through modulation of the tumor vasculature and permitted
enhanced penetration of NPs into the tumor.
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Rapamycin (RAPA), an mTOR inhibitor, inhibits pri-
mary and metastatic tumor growth by antiangiogen-
esis through decreasing the production of vascular
endothelial growth factor (VEGF) and lowering the
response of vascular endothelial cells to stimulation
by VEGF.15,16 Recent studies have shown that RAPA
also mediates vascular renormalization, resulting in
improved tumor perfusion.17 While RAPA cannot be
effectively administered via intravenous (IV) injection,
its hydrophobicity can be employed to facilitate the
encapsulation of RAPA into PLGA NPs. While this has
been achieved previously, a high drug loading was
difficult to attain due to incompatibility between the
drug and polymer matrix.18 It is known that RAPA can
sensitize cells to cisplatin through the down regulation
of antiapoptotic proteins such as p53-induced
p21.1921 As a result, combination therapy with both
cisplatin and RAPA can utilize the synergy between
both drugs for enhanced anticancer efficacy. Yet,
current efforts at encapsulating cisplatin into PLGA
NPs through the double emulsionmethod are severely
hampered by a low drug loading and the presence of
burst drug release.1
Previously, we have developed lipid-coated calcium
phosphate cores with a surface layer coating of dio-
leoylphosphatidic acid (DOPA). The hydrophobic cores
are capable of efficiently encapsulating gemcitabine
triphosphate,22 small interfering RNA (siRNA),23 DNA,24
peptides,25 and other types of hydrophilic phosphory-
lated drugs. In an effort to exploit this method for
cisplatin encapsulation, a formulation was developed
where cisplatin composes both the drug and the nano-
carrier itself. These DOPA-coated cisplatin cores,25,26
which are composed entirely of cisplatin, are charac-
terized by a substantial drug loading and share similar
surface properties with oleic acid coated iron oxideNPs
(IONP) and quantum dots (QD).2730 Since IONPs and
QDs have been efficiently loaded into PLGA NPs and
enhanced the encapsulation of hydrophobic drugs
alongside them, we hoped to coencapsulate our cis-
platin cores, along with RAPA into PLGA NPs using the
solvent displacement method. Sigma receptors are
well-known membrane-bound proteins that show
high affinity for neuroleptics and are overexpressed
on many human tumors including melanoma.3133
Therefore, anisamide, an agonist of sigma receptors,
was conjugated to PLGAPEG to enhance the delivery
of drugs into A375-luc human melanoma cells.
Herein, we report an efficient coencapsulation of
both cisplatin cores and RAPA into micelle-like PLGA-
PEG-anisamide (MBA) NPs using the solvent displace-
ment method (Scheme 1). Anticancer efficacy of this
formulation was investigated both in vitro and in vivo.
We hypothesized that codelivery of both drugs would
result in enhanced anticancer efficacy by modulating
the tumor microenvironment to improve the penetra-
tion of PLGA NPs into the tumor. The study was
performed in a xenograft model of human melanoma.
RESULTS AND DISCUSSION
Encapsulation of Cisplatin Cores and RAPA into PLGA NPs
Using Solvent Displacement Method. Cisplatin is a first-line
therapy against a wide spectrum of solid neoplasms.
However, systemic toxicities including nephro- and
neurotoxicities along with drug resistance severely
limit the use of cisplatin in the clinical setting.3436
In an effort to overcome the associated nephro- and
neurotoxicities, attempts to encapsulate cisplatin into
NPs were made. However, these attempts were ham-
pered by the poor solubility of cisplatin inwater and oil.
By exploiting this previous barrier to our advantage, we
have succeeded in the synthesis of cisplatin cores with
substantial drug loading through a reverse microemul-
sion method.26 The resulting cisplatin cores are com-
posed entirely of cisplatin and stabilized by DOPA with
a drug loading of approximately 93 wt % and have
tunable sizes between 12 and 75 nm.25,26 After being
coated with an outer leaflet lipid layer, cisplatin cores
Scheme 1. Efficient co-encapsulation of cisplatin cores and RAPA into PLGA NP using a solvent displacement techniquea
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demonstrated potent antitumor effects both in vivo
and in vitro.
It is notable that the hydrophobic surface coating of
cisplatin cores permits their solubility in organic sol-
vents including hexane, chloroform, and tetrahydro-
furan (THF).26 Here, we attempted to encapsulate
cisplatin cores inside PLGA NPs (cisplatin PLGA NPs)
using the solvent displacement method (Scheme 1).
THF is a water-miscible, volatile solvent and is versatile
for dissolving a variety of hydrophobic compounds.
Thus, THF was selected as the solvent along with water
as the antisolvent for solvent displacement process.
When the PLGA-PEG-MBA polymer was self-assembled
into NPs, hydrophobic cisplatin cores (∼12 nm) were
efficiently encapsulated into PLGA NPs through hydro-
phobic interaction. The drug loading (DL) of cisplatin
cores was determined using inductively coupled plas-
ma mass spectrometry (ICP-MS) (Figure 1A). When the
feed ratio of cisplatin cores was lower than 5.0 wt %,
the encapsulation efficiency (EE) was higher than 90%.
Notably, over 82%of cisplatin cores were encapsulated
and a 12 wt % DL was achieved when the feed ratio of
cisplatin cores was at 15 wt %. This is the first time that
cisplatin has been encapsulated into PLGA NPs using
solvent displacement, and its DL is much higher than
other current cisplatin PLGA formulations. In addition,
DLS results showed cisplatin PLGA NPs were approxi-
mately 80 nm in size and exhibited a monodisperse
distribution (Figure 1B).
Our success in efficiently loading cisplatin cores
into PLGA NPs offers a new opportunity to codeliver
two drugs for combination therapy. For example,
hydrophobic cisplatin cores can be engineered into
PLGA NPs with other hydrophobic anticancer drugs
simultaneously, such as paclitaxel and RAPA. Here,
RAPA was further chosen and encapsulated into PLGA
NPs alongside cisplatin cores, due to its synergy with
cisplatin. The loading of RAPA was measured using
HPLC. The first attempts at loading RAPA alone within
PLGA NPs (RAPA PLGA NPs) at a feed ratio of 5.0 wt %
resulted in a low EE of only 23%, correlating to a DL of
1.15 wt % (Figure 1C). It is because RAPA is encapsu-
lated into the polymer matrix of PLGA NPs through
hydrophobic interactions. Therefore, the encapsula-
tion is limited by the compatibility between RAPA
and the hydrophobic block copolymer.3739 However,
when RAPA was coencapsulated alongside 4.5 wt %
cisplatin cores at a 5.0 wt % feed ratio (combinatory
PLGANPs), the EE andDL of RAPA in combinatory PLGA
NPs were subsequently increased to 80% and 4.0 wt %
(Figure 1D), respectively. Therefore, we noticed that
the presence of cisplatin cores significantly enhanced
the DL of RAPA by 3.5-fold. Even when the feed ratio of
RAPA was decreased to 2.5 wt % alongside 4.5 wt % of
cisplatin cores, the DL of RAPA in combinatory PLGA
NPswas 2.2 wt% and the EE of RAPAwas still facilitated
by 2.8-fold in the presence of the cisplatin cores. This
finding is consistent with previous observations that
oleic acid coated NPs can enhance encapsulation of
hydrophobic drugs in PLGA NP.4042 DLS results con-
firmed that the size andmonodispersity of all PLGANPs
was not affected by the encapsulation of RAPA, cispla-
tin cores, or both drugs in a single NP (Figure S1,
Supporting Information).
Figure 1. DL and EE of cisplatin PLGANPs (A); size and PDI (polydispersity index) of cisplatin PLGANPs (B); EE of RAPA in PLGA
NPs in the absence or presence of 4.5 wt % cisplatin cores (C); DL of RAPA in PLGA NPs in the absence or presence of cisplatin
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Analysis of the physical characteristics of all PLGA
NPs was performed by transmission electron micro-
scopy (TEM). PLGA NPs were spherical with a diameter
of approximately 50 nm (Figure 2, AC), smaller than
the value determined by dynamic light scattering (DLS)
(Figure 1 and Figure S1, Supporting Information). TEM
analysis also revealed that increases in the feed ratio of
cisplatin cores resulted in subsequent increases in the
average number of cisplatin cores per PLGA NP
(Figure 2, A and B). However, the morphology and
loading of cisplatin cores was unaffected by the pres-
ence of RAPA (Figure 2, B and C). We have analyzed
over 100 PLGA NPs to determine the distribution
profile regarding the average number of cisplatin
cores. The distribution profiles for three different for-
mulations were determined with two different con-
centrations of cisplatin cores and one (RAPAþ cisplatin
cores) combination. Figure 2D indicates that the vast
majority of PLGA NPs contained one to three cisplatin
cores. Therefore, most of our NPs are able to utilize the
synergy between cisplatin and RAPA. We calculated
the average number of cisplatin cores as 0.74, 1.5, and
1.6 for PLGA NPs with 1.9 wt % cisplatin cores, 4.5 wt %
cisplatin cores, and (2.2 wt % RAPAþ 4.5 wt % cisplatin
cores) ratios, respectively (Figure 2E). These results
indicate that the incorporation of RAPA into PLGA
NPs did not affect the loading of cisplatin cores. The
distribution profile for (2.2 wt % RAPA þ 4.5 wt % cis-
platin cores) combinatory PLGA NPs (Figure 2, D and E)
indicates that only ∼20% of PLGA NPs did not contain
cisplatin NPs. Because empty RAPA PLGA NPs can only
achieve a low loading of RAPA (Figure 1. C), we can
conclude that the vast majority of RAPA was coencap-
sulated alongside cisplatin cores and only a small
amount of RAPA was encapsulated alone in PLGA NPs.
Therefore, this is the first time that hydrophobic
cisplatin cores and RAPA were coencapsulated into a
single PLGA NP with a high drug loading through a
solvent displacement method. Furthermore, cisplatin
cores were found to further enhance the loading of
RAPA into PLGA NPs. Because of the flexibility of this
platform, further investigations into the interaction
between hydrophobic, inorganic NPs, and hydropho-
bic drugs may lead to the development of new,
efficient drug loading mechanisms tuned for facilitat-
ing the codelivery of drugs working at synergistic
ratios. Co-encapsulation of multiple agents with di-
verse physicochemical properties, such as calcium
phosphate cores loaded with gemcitabine and macro-
molecular siRNA, may be possible.22,24
Cellular Uptake of PLGA NPs in A375-luc Melanoma Cells.
The use of anisamide to bind overexpressed sigma
Figure 2. TEM images of PLGA NPs loaded with 1.9 wt % of cisplatin cores (A), 4.5 wt % of cisplatin cores (B), and 2.2 wt % of
RAPAand 4.5wt%of cisplatin cores (C). All NPswere negatively stainedwith uranyl acetate. The number of cisplatin cores per
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receptors on human tumors is a well-known and
accepted method for achieving preferential NP accu-
mulation in tumors. Sigma receptors are well-known
membrane-bound proteins that show high affinity for
neuroleptics and are overexpressed on many human
tumors including melanoma, non-small cell lung carci-
noma, breast tumors of neural origin, and prostate
cancer.3133 Sigma receptors bind to haloperidol and
various other neuroleptics showing a high affinity
with the anisamide moiety. We therefore synthesized
PLGA-PEG-MBA (as described in Figure S2, Supporting
Information) for the enhanced delivery of RAPA and
cisplatin cores into A375-luc melanoma tumor cells.
In vitro cellular uptake of PLGA-PEG-MBA NPs was
measured using ICP-MS. Compared to the free drugs
alone, PLGA-PEG-MBA NPs loaded with only cisplatin
cores, or cisplatin cores alongside RAPA, facilitated
greater cellular uptake of cisplatin in A375-luc cells
than the treatments not utilizing anisamide (Figure S3,
Supporting Information). Quantitative ICP-MS results
clearly indicated that the MBA ligand furthered NP
uptake by approximately 2-fold. Receptor competition
experiments further showed that haloperidol could
effectively compete with MBA in binding to sigma
receptors on A375-luc cells, suggesting MBA modifica-
tion induced sigma receptor-mediated endocytosis
(Figure S3, Supporting Information). Because of the
advantages of employing anisamide mediated cell
uptake, all PLGA NPs were composed of PLGA-PEG-
MBA containing the specified drug or drugs unless
otherwise stated.
Cell Toxicity and in Vitro Synergistic Effects. It has been
reported that RAPA is capable of sensitizingmelanoma
cells to cisplatin.1921 PLGA NPs loaded with a 4.5 wt %
of cisplatin cores and 2.2 wt % of RAPA corresponding
to a cisplatin/RAPAmolar ratio of 5.5:1were formulated
to employ this synergy. First, we evaluated the degree
of synergy between free RAPA and cisplatin by char-
acterizing their cytotoxicity toward A375-luc cells in
vitro separately and in combination. The IC50 of free
cisplatin and RAPA administered separately was 10 and
16 μM, respectively. However, a combination of free
cisplatin and RAPA resulted in a much lower IC50 of
0.82 μM (based on the concentration of cisplatin)
(Figure 3, A). A combination index (CI) was determined
using the ChouTalalay isobologram equation.13,14
The CI at the IC50 of the free drug combination was
0.36, indicating strong synergism. For the NPs, the IC50
of cisplatin PLGA NPs and RAPA PLGA NPs were 2.1
and 1.2 μM, respectively, which demonstrated 5- and
13-fold decreases over free cisplatin and RAPA, respec-
tively (Figure 3, B). Yet, coencapsulation of both drugs
into single PLGA NP permits an even lower IC50. In the
combinatory PLGA NPs, the IC50 achieved through
coencapsulation was approximately 0.3 μM (based on
the concentration of cisplatin). The CI at the IC50 was
0.5, which also indicated synergism. In addition, empty
PLGA NPs did not induce any cytotoxicity (Figure S4,
Supporting Information).
After treatment, A375-luc cell apoptosis was as-
sayed using FITC-Annexin V/PI staining. The number
of apoptotic cells was then quantified using flow
cytometry (Figure 3, C). Results indicated that RAPA
significantly sensitized A375-luc melanoma cells to
apoptosis induced by cisplatin, possibly becausemTOR
inhibitors sensitize tumor cells to cisplatin by blocking
the up-regulation of p21 and inducing apoptosis as a
result.1921
Because the presence of cisplatin cores greatly
enhanced the loading of RAPA into PLGA NPs, the
efficacy of a formulation composed of two separate
NPs, RAPA PLGA NPs, and cisplatin PLGA NPs
Figure 3. Cell toxicity of free RAPA, cisplatin, and their combination in A375-luc cells (A); cell toxicity of RAPA PLGA NPs,
cisplatin PLGANPs, and combinatory PLGANPs in A375-luc cells (B). IC50 of free drug combination and combinatory PLGANPs
were calculated based on the concentration of cisplatin. Cells were stained with Annexin V-FITC/PI, and the number of
apoptotic cells was counted by flow cytometry. Apoptosis of A375-luc cells induced by incubationwith drugs for 24 h (C). The
loading of cisplatin cores and RAPA in combinatory PLGA NPs was 4.5 and 2.2 wt %, respectively; the loading of cisplatin in
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administered as separate nanoparticles was not deter-
mined. It is believed that the loading of RAPA in this
case would be insufficient to achieve the synergistic
ratio with cisplatin. Additionally, the efficacy of the
combination therapy relies heavily on maintaining the
synergistic ratio between cisplatin and RAPA. With two
separate NPs, the ratio may not be effectively main-
tained in vivo because their distributions may vary
following administration. Thus, the in vitro and in vivo
anticancer efficacy of RAPA PLGA NPs, cisplatin PLGA
NPs, and combinatory PLGA NPs were compared, but
anticancer activity of a combination of cisplatin PLGA
NPs and RAPA PLGA NPs was not tested.
Sustained Release of RAPA and Cisplatin without Burst
Release. To fully utilize the advantages of combination
therapy, the in vitro release of both drugs at the desired
molar ratio for employing synergy is crucial. We mea-
sured the release of cisplatin and RAPA from combi-
natory PLGA NPs using ICP-MS and high-performance
liquid chromatography (HPLC) (Figure 4). Combinatory
NPs showed sustained release of both cisplatin and
RAPA. Moreover, combinatory PLGA NPs exhibited a
similar release rate for both cisplatin and RAPA, which
will further enhance the synergistic effects as expected.
In addition, the release rate of cisplatin from combina-
tory PLGA NPs was only slightly affected by the pres-
ence of RAPA. The release of RAPA from combinatory
PLGA NPs followed the same pattern as the release of
cisplatin. It is notable that no burst release pattern was
observed. In vitro release results indicated the burst
release of cisplatin from cisplatin PLGA NPs was cir-
cumvented by the hydrophobic DOPA coating, which
is very difficult to achieve in other PLGA-based cisplatin
particles. As a result, the encapsulation of hydrophilic
drugs in lipid-coated cores may offer a novel strategy
to overcome the prominent burst release issue.
Pharmacokinetics and Biodistribution. In order to study
the pharmacokinetics (PK) and biodistribution of both
the drugs and the PLGA carrier, two methods were
used. Quantification of RAPA and PLGA was achieved
through a 14C and 3H label, respectively, while the
concentration of cisplatin was determined through
ICP-MS. The PK datawere fittedwith a non-compartment
model using the WinNonlin program. The PK experi-
ment indicated a prolonged blood circulation time for
the combinatory PLGA NPs (Figure 5, A). After intrave-
nous injection, about 40% of the combinatory PLGA
NPs were still in the blood after 1 h, while the free drug
was rapidly cleared within 20 min.43 The t1/2 is about
2.5 h. It was found that there was no significant differ-
ence in PK among 14C labeled RAPA (14C-RAPA), cispla-
tin, and 3H-labeled combinatory PLGA NPs (Figure 5, A),
indicating negligible release of drugs from combinatory
PLGA NPs during the circulation. Eight hours post-iv
injection, 6.0%of the injected dose per gramof cisplatin
in combinatoryNPs accumulated in the tumor (Figure 5, B),
which was significantly higher than free CDDP.25
Meanwhile, the accumulation ratio of 14C-RAPA/cisplatin/
3H-labeled combinatory NPs was near 1:1:1. Therefore,
combinatory PLGA NPs delivered cisplatin and RAPA at
synergistic ratio into tumor without significant release
of drug during the circulation in the blood. It was also
found that liver was themajor organ to clear PLGANPs,
Figure 4. In vitro release kinetics of cisplatin and RAPA in
PBS at 37 C from PLGA NPs. The loading of cisplatin cores
and RAPA in combinatory PLGA NPs was 4.5 and 2.2 wt %,
respectively; the loading of cisplatin in cisplatin PLGA NPs
was 4.5 wt %; the loading of RAPA in RAPA PLGA NPs was
0.8 wt %.
Figure 5. Pharmacokinetics (A) and biodistribution (B) of combinatory NPs in A375-luc tumor-bearing nude mice. PLGA and




GUO ET AL . VOL. 8 ’ NO. 5 ’ 4996–5009 ’ 2014
www.acsnano.org
5002
which is consistent with the biodistribution of other
PLGA NPs.44
In Vivo Combinatory PLGA NPs Inhibited the Growth of A375-
luc Xenograft Tumor Notably and Safely. As previously men-
tioned, one of themost fundamental principles behind
this formulation is based on the observation that
cisplatin cores significantly enhanced the loading of
RAPA into PLGA NPs. Therefore, it would be intuitive
and convenient to codeliver cisplatin cores and RAPA
in a single nanoparticulate formulation at a synergistic
ratio in vivo.
Mice bearing subcutaneous A375-luc tumors were
treated with a dose of 0.15 mg/kg RAPA or 0.3 mg/kg
cisplatin on aweekly basis. The combinatory treatment
group was given both drugs at the previous ratio on a
weekly basis. As shown in Figure 6, combinatory PLGA
NPs exhibited significant anticancer activity without
reducing the body weight of treated animals. We also
showed that combinatory PLGA NPs were more effica-
cious than a mixture of RAPA PLGA NPs and cisplatin
PLGA NPs administered at the same time in different
carriers (Figure 6), further verifying the importance of
codelivery of synergistic drugs in the same carrier to
maintain the synergistic ratio of drugs in the tumor
cells both in vitro and in vivo. H&E staining further
confirmed the absence of observable nephrotoxicity
(Figure S5, Supporting Information), thus supporting
the basis that combinatory PLGA NPs are both effica-
cious and safe.
Combinatory PLGA NPs Reduced Stroma and Induced Sig-
nificant Apoptosis of TAFs and Tumor Cells. A dense extra-
cellular matrix (ECM) and the stromal components of
tumors contribute to an increased interstitial fluid
pressure (IFP), which severely hampers efficient pene-
tration of NPs into the tumor.45 As a result, cells distal
from blood vessels are resistant to systemic therapy
because of low drug availability. Hence, targeting non-
neoplastic components within the microenvironment
provides an alternative opportunity for developing
more effective therapy.
Therapeutic evaluations showed that combinatory
PLGA NPs exhibited considerable anticancer effi-
cacy even when administered weekly at a low dose
(0.3 mg/kg cisplatin; 0.15 mg/kg RAPA). We postulated
that the success in tumor growth inhibition may be
induced bymicroenvironment specific effect. By weak-
ening the protective tumor microenvironment, drug-
loaded NPs exhibited enhanced penetration into tu-
mor cells and subsequently enhanced efficacy. We
therefore examined whether treatments affected the
tumor microenvironment. First, collagen, a major ex-
tracellular matrix component, was stained using
Masson Trichrome assay. As shown in Figure 7, combi-
natory PLGA NP treatment significantly reduced the
amount of collagen (blue) by approximately 80%
compared to an untreated control. However, we ob-
served that cisplatin PLGA NPs and RAPA PLGA NPs
were unable to reduce as much collagen.
As collagen is secreted by TAFs (tumor-associated
fibroblasts), the effect of this treatment on TAFs was
further investigated by staining for R-smooth muscle
actin (SMA), a marker of TAFs.46 Apoptosis was con-
firmed through terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) (Figure 8). As shown in
Figure 8, cisplatin PLGA NPs and combinatory PLGA
NPs induced significant apoptosis in tumor cells,
greatly reduced the fibroblast population, and there-
fore, potentially decreased the level of collagen. Five
randomly selected microscopic fields contained 0.4%
TUNEL-positive cells on average in the control group,
7.8% in the RAPA-treated group, 14.2% in the cisplatin-
treated group, and 66.2% in the combination therapy
group. R-SMA staining results supported that A375-luc
xenograft tumors are abundant in TAFs because 25.1%
of control group cells were TAFs. Combinatory PLGA
NPs almost completely depleted these cells with only
2.2% SMA-positive cells remaining following combina-
tory treatment. Nevertheless, RAPAPLGANPs alone did
not affect the amount of TAFs. It is notable that MBA-
modified combinatory PLGA NPs not only affected
Figure 6. Effects of empty PLGANPs, RAPA PLGANPs, cisplatin PLGANPs, mixture of cisplatin PLGANPs and RAPA PLGANPs,
and combinatory PLGA NPs on tumor growth (A) and body weight (B) respectively of A375-luc tumor bearing mice. The
arrowheads indicate the time of injection. RAPA was administered intravenously at a dose of 0.15 mg/kg; cisplatin was
administered intravenously at a dose of 0.3mg/kg. The loading of cisplatin cores and RAPA in combinatory PLGANPs was 4.5
and 2.2wt%, respectively; the loadingof cisplatin cores in cisplatin PLGANPswas 4.5wt%; the loadingof RAPA in RAPAPLGA
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tumor cells but also depleted TAFs. This observation
indicates that while MBA can enhance the uptake of
combinatory PLGA NPs by tumor cells, its delivery is
not specific to tumor cells only. Through depletion of
TAFs and a reduction of collagen expression, combi-
natory PLGA NPs may achieve a greater perfusion of
NPs into tumor cells for enhanced therapeutic effects.
Thus, the presence of RAPA greatly modulated the
tumor microenvironment to facilitate enhanced drug
penetration and efficacy. However, RAPA alone is still
less effective than a combination of cisplatin and RAPA
at a synergistic ratio.
Combinatory NPs Showed an Antiangiogenesis Effect and
Normalized Tumor Vessels. Angiogenesis is required for
invasive tumor growth and metastasis. Therefore, it
constitutes an important point in the control of cancer
progression and a target to inhibit further growth.47
Unlike normal blood vessels, the tumor vasculature is
abnormally composed, resulting in the formation of
physiological barriers which hamper the delivery of
therapeutic agents into tumors.48 Therefore, antiangio-
genic imbalances in the tumor results in tumor vascu-
lature normalization and thus improves NP delivery
and accumulation in the tumor.48 Combination of
Figure 7. Tumor sections were stained with Masson Trichrome. The blue color represents collagen content, and the
cytoplasm is stained red. The collagen content of five randomly selected microscopic fields was quantified using ImageJ. *
indicates P < 0.05; ** indicates P < 0.01. The scale bar represents 100 μm.
Figure 8. TAFswere stained byR-SMA antibody (red) and apoptosis of cells in A375-luc tumorswas indicated by TUNEL assay
(green). Nuclei are stained blue. The percentage denotes the average percentage of R-SMAþ fibroblasts (red) and the
percentage of TUNEL positive cells (green), respectively. Five randomly selected microscopic fields were quantitatively
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cytotoxic therapies and antiangiogenic treatment dur-
ing the vascular normalization also exhibits synergistic
effects.
To study the antiangiogenesis effect of the NPs,
blood vessels were stained using an anti CD31 anti-
body (Figure 9). Mice treated with RAPA PLGA NPs
alone and combinatory PLGA NPs exhibited a marked
decrease in the number of vessels in tumor. However,
the number of blood vessels in the tumor in mice
treated with cisplatin PLGA NPs alone was only slightly
affected by the treatment. In addition, blood vessel
normalization was observed with RAPA treatment
groups, consistent with previous reports in breast
cancers.17,45,49 Normalization may enhance transvas-
cular flux and improve the delivery of NPs to the tumor.
To characterize blood flow, the vessel area was quanti-
fied by ImageJ and normalized to data from the control
group. RAPA PLGA NPs and combinatory PLGA NPs
significantly re-expanded the microvasculature and
increased the vessel area by approximately 2.5- and
3-fold over the PBS control group, respectively
(Figure 9). However, NP formulations employing only
cisplatin without RAPA did not exhibit blood vessel
normalization.
Combinatory PLGA NPs Improved NP's Penetration in A375-luc
Tumor. Anelevated IFP, a physical barrier from the extra
cellular matrix, hinders the delivery of drugs into the
dense collagen matrix.45 Our studies have shown that
combinatory PLGA NPs modulated the stroma by
depleting TAFs and decreasing the amount of collagen.
In order to study whether these treatment regimens
affect the distribution of NP's in A375-luc tumor, DiI
containing PLGA NPs (DiI PLGA NPs) were injected
following the therapy experiment and mice were
sacrificed 24 h post intravenous administration. The
blood vessels of tumorwere stained using an anti CD31
antibody (green). As shown in Figure 10, RAPA PLGA
NPs and combinatory PLGA NPs re-expanded the
abnormal blood vessels and decreased the number
of blood vessels compared to the untreated group,
which is consistent with data mentioned above. In an
IFP elevated, untreated tumor, major DiI PLGA NPs
were trapped in blood vessels and were unavailable to
tumor cells. Although RAPA PLGA NPs enhanced
penetration of DiI PLGA NPs, the enhancement was
unimpressive. As expected, cisplatin PLGA NPs and
combinatory NPs ablated the physical barrier and
significantly improved NP delivery into the tumor.
Mechanism of RAPA for Enhancing the Therapeutic Efficacy of
Cisplatin. As observed through both clinical and re-
search data, weakening the tumor stroma has proven
successful in enhancing the efficacy of chemotherapy.
For example, abraxane was combined with gemcita-
bine to treat pancreatic cancer in a phase I/II study.50,51
The combination showed significant anticancer effi-
cacy with a 48% response rate, which was attributed to
the depletion of stroma for enhanced penetration of
gemcitabine inside the pancreatic tumor. Preclinical
data have also shown that PEGylated Cellax reduced
the content of R-smooth muscle actin, which is a
marker of TAFs, in 4T1 and MDA-MB-231 orthotopic
breast tumor models.5 Cellax treatment significantly
Figure 9. Antiangiogenesis effect of treatments on the A375-luc xenograft tumor was investigated by CD-31 staining (red).
Nuclei were stained blue. The number denotes the average number of CD-31 positive vessels per microscopic field. Vessel
area, quantified using ImageJ, was normalized to a PBS treated control. Five randomly selected microscopic fields were
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decreased the IFP of tumor. As a result, the perfusion of
active drugs into tumors was significantly enhanced,
resulting in a notable tumor growth inhibition. These
studies indicated the importance of overcoming
stroma-induced barriers in cancer treatment.
In this study, we have successfully engineered
combinatory PLGA NPs employing both RAPA and
cisplatin at a synergistic ratio. Combinatory PLGA
NPs were able to significantly modulate the tumor
microenvironment against further tumor proliferation
(illustrated in Figure 11) and induce notable anticancer
efficacy. mTOR inhibitors, such as RAPA, can suppress
tumor proliferation by hindering tumor angiogenesis
and blood vessel normalization as studied previ-
ously.52 While RAPA PLGA NPs alone were able to
decrease the number of blood vessels through anti-
angiogenic activity and normalize blood vessels,52 they
were unable to significantly enhance penetration of
PLGA NPs into the tumor through microenvironment
modulation as illustrated in Figure 10. Thus, compared
to cisplatin PLGA NPs and combinatory PLGA NPs,
RAPA PLGA NPs exhibited the most minimal tumor
inhibition of the three (Figure 6). Similarly, cisplatin
PLGA NPs alone showed partial antiangiogenic activ-
ities (Figure 9), probably through the inhibition of
endothelial cells. Yet, normalization of blood vessels
did not occur in tumors from mice treated with cispla-
tin PLGA NPs alone. Compared to RAPA PLGA NPs,
however, cisplatin PLGA NPs did deplete a significant
amount of TAFs and down-regulate their collagen
expression (Figures 7 and 8). By ablating physical
barriers that limited the deep penetration of NPs into
the tumor (Figure 10), cisplatin PLGA NPs induced
considerable anticancer efficacy (Figure 6). However,
Figure 10. Fluorescent images of the tumor section showed that combinatory NPs improved the penetration of DiI PLGA NP
in an A375-luc xenograft. The blood vessels were stained using an anti CD31 antibody (green); the cell nucleus was stained
using DAPI (blue); the PLGA NP was labeled with DiI (red). The scale bar represents 50 μm.
Figure 11. RAPA and cisplatin combination remodeled the tumor microenvironment. Combinatory PLGA NPs exhibited a
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their efficacies were far less significant compared to
the combinatory PLGA NPs. Combinatory PLGA NPs
not only depleted TAFs and decreased the amount of
collagen to foster improved penetration of NPs into the
tumor (Figure 10) but also significantly modulated the
tumor microenvironment by re-expanding blood ves-
sels and increasing blood flow to promote PLGA NP
accumulation in the tumor. Because of the synergy
between RAPA and cisplatin, the combinatory PLGA
NPs induced significant apoptosis on tumor cells
in vitro and in vivo (Figure 3 and 8). This modulation
of the tumor microenvironment therefore permits a
substantial enhancement in the efficacies of the fol-
lowing chemotherapy treatments. As a result, combi-
natory PLGANPs at a lowdose of RAPA and cisplatin on
a weekly dosing schedule significantly inhibited the
growth of tumor (Figure 6).
The tumor microenvironment is composed of the
surrounding blood vessels, immune cells, fibroblasts,
pericytes, endothelial cells, signaling molecules, and
the extracellular matrix,53 and many important molec-
ular targets in the microenvironment have been
identified.54 Therefore, the tumor microenvironment
has become an important aim for maximizing the
effects of chemotherapy through combination ther-
apy. For example, recent studies have shown that the
administration of low dose TGF-β inhibitor significantly
decreases the IFP in the tumor and therefore enhances
the accumulation and penetration of NPs.55,56 How-
ever, the hydrophobicity of the TGF-β inhibitor limits its
use and the encapsulationmultiple drugs intoNPswith
diverse physicochemical properties has previously pro-
ven difficult. However, our delivery system holds the
potential to encapsulate both cisplatin and hydropho-
bic drugs in a single formulation. Previously, our la-
boratory has successfully encapsulated drugs such as
gemcitabine triphosphate,22 siRNA, DNA,23 peptide,25
and other types of hydrophilic phosphorated drugs
into DOPA-coated calcium phosphate cores. Although
these drugs are diverse in molecular weight and
solubility, they might be easily coencapsulated into
PLGA NPs in a similar manner, as they have similar
surface properties with cisplatin cores. Drug loaded
DOPA-LCP cores may also be able to enhance the
encapsulation of hydrophobic drugs. Therefore, this
PLGA NP platform can open a window for the study of
the synergistic effects between chemotherapydrugs and
antistromal drugs and to maximize therapeutic efficacy.
CONCLUSIONS
We have developed PLGA NPs capable of coencap-
sulating cisplatin cores and RAPA to alter the tumor
microenvironment for enhanced drug accumulation
and further anticancer efficacy. This is the first method
to encapsulate cisplatin directly into PLGA NP with
efficient loading and encapsulation using solvent dis-
placement technique. When coencapsulated with
RAPA, cisplatin cores improved the loading of RAPA
by 3.5-fold. A controlled release profile without burst
release was demonstrated for both cisplatin and RAPA
in the combinatory PLGA NPs. Therefore, the cytotoxi-
city of the combineddrugswas considerably enhanced
by PLGA NP delivery system. When combined, RAPA
and cisplatin cores in PLGA NPs reduced the number of
TAFs and level of collagen expression within xenograft
tumors, demonstrated an antiangiogenesis effect, nor-
malized tumor blood vessels, and improved the pene-
tration of NPs in tumor. We propose that these findings
canbeextended to thedevelopmentof new theranostic
formulations allowing imaging agents, such as IONPs,
QDs and up-conversion NPs, to be combined. Hydro-
phobic and lipid-coated cores containing drugs, such as
siRNA containing lipid-coated calcium phosphate cores,
can also be efficiently coloaded to treat a variety of
diseases with the advantage of utilizing the synergistic
activity between individual drug components.
MATERIALS AND METHODS
Materials. tBOC-PEG3500-NH2 3HCl and mPEG3000-NH2 3HCl
were ordered from JenKem Technology USA, Inc. (Allen, TX).
Acid-terminated PLGA (lactide/glycolide (50:50)) was purchased
from DURECT Corporation (Pelham, AL). Cisplatin was pur-
chased from Acros Organics (Fair Lawn, NJ). RAPA was pur-
chased from ChemieTek (Indianapolis, IN). Hexanol, Triton
X-100, cyclohexane, p-anisic acid, 1-ethyl-3-(3-(dimethylamino)-
propyl)carbodiimide (EDC),N-hydroxysuccinimide (NHS), andN,
N-diisopropylethylamine (DIPEA) were obtained from Sigma-
Aldrich (St. Louis, MO). DOPA was purchased from Avanti Polar
Lipids (Alabaster, AL). 3H-Labeled paclitaxel[o-benzamido-3H(N)]
and 14C-labeled stearic acid were purchased from Moravek
Biochemicals and Radiochemicals (Brea, CA).
Preparation of DOPA-Coated Cisplatin Cores. DOPA-coated cispla-
tin cores were prepared according to our previous publi-
cations,25,26 dispersed in THF, and stored in a glass vial for
further use.
Preparation of PLGA/PLGA-PEG-MBA (1:1 wt/wt) NPs Loaded with
Different Cargos. The drugs were loaded into PLGA NPs using
the solvent displacement method. Typically, the drugs and
10 mg of polymers were dissolved in 200 μL of THF and added
dropwise into 2mL of water under stirring at room temperature.
The resulting NP suspension was allowed to stir uncovered for
6 h at room temperature to remove THF. The NPs were further
purified by ultrafiltration (15 min, 3000g, Amicon Ultra, Ultracel
membrane with 50000 NMWL, Millipore, Billerica, MA). Then, the
PLGA-PEG NPs were resuspended, washed with water, and
collected likewise. The amount of cisplatin was measured using
a Varian 820-MS inductively coupled plasma-mass spectrometer
(ICP-MS). The amount of RAPA was measured using high-
performance liquid chromatography (HPLC) (Waters Corp., Milford,
MA). EE and DL were calculated according to the formulas
EE ¼ amounts of drug in NPs
total amount of drug
 100%
DL ¼ amount of drug in NPs
total weight of NPs
 100%
In Vitro Release of Cisplatin and RAPA from PLGA NPs. RAPA
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chromatography (HPLC), using CLC-ODS-18 column (5 cm, 4.6
150mm;Waters Corp., Milford, MA)maintained at 25 C, with an
ultraviolet detector at 277 nm. The mixture of 60% acetonitrile
and 40% water (v/v) was used as a mobile phase and delivered
at a flow rate of 0.5 mL min1. The injection volume was 20 μL,
and the retention time was about 5 min. In addition, Pt con-
centrations were measured using ICP-MS.
The dialysis technique was employed to study the release of
RAPA and cisplatin from different PLGA NPs in phosphate-
buffered saline (PBS) (pH 7.4) with 0.25% Tween-80. RAPA-
loaded micelles with a final RAPA concentration of 0.85 mg/mL
were placed into a dialysis tube with a molecular weight cutoff
of 3000 Da and dialyzed against 15 mL of PBS (pH 7.4) with
0.25% Tween-80 in a thermocontrolled shaker with a stirring
speed of 200 rpm at 37 C. Samples of 200 μL were withdrawn
at specified times. RAPA concentration was determined by
RP-HPLC; Pt concentrations were measured using ICP-MS.
The samples taken for measurement were replaced with
fresh media, and the cumulative amount of drug released into
the media at each time point was calculated as the percentage
of total drug released to the initial amount of the drug. All
experiments were performed in duplicate and the data re-
ported as the mean of three individual experiments.
Apoptosis Assays. Quantification of apoptosis by Annexin
V/propidium iodide (PI) staining was performed using a BD
ApoAlert annexin V-FITC Apoptosis Kit (BD Biosciences, San
Jose, CA) according to the manufacturer's instructions. Both
floating and attached cells were collected 24 h after drug
treatment. The concentration of RAPA was 0.36 μM, and the
concentration of cisplatin was 2.0 μM. The molar ratio of
cisplatin to RAPA was 5.5. Cells were analyzed on a FACS Calibur
flow cytometer using CellQuest Pro software (version 5.1.1; BD
Biosciences, San Jose, CA).
In Vivo Anticancer Efficacy. Animals were maintained in the
Center for Experimental Animals (an AAALAC accredited experi-
mental animal facility) at the University of North Carolina. All
procedures involving experimental animals were performed in
accordance with the protocols approved by the University of
North Carolina Institutional Animal Care and Use committee
and conformed to the Guide for the Care and Use of Laboratory
Animals (NIH publication no. 86-23, revised 1985). Female
athymic nude mice, 56 weeks old and weighing 1822 g,
were supplied by theUniversity of North Carolina animal facility.
Five million A375-luc cells were injected subcutaneously into
the mice. After 8 days, the mice were randomly divided into six
groups (four mice per group). The mice were treated with
weekly IV injections of PLGA NPs and saline as a control. A dose
of 0.3 mg/kg of Pt and 0.15 mg/kg of RAPA was administered.
Thereafter, tumor growth and body weight were monitored.
Tumor volume was calculated using the following formula:
TV = (LW2)/2, withW being smaller than L. Finally, mice were
sacrificed using a CO2 inhalation method. After the therapeutic
experiment was done, major organs were collected after treat-
ment and were formalin fixed and processed for routine H&E
staining using standardmethods. Imageswere collected using a
Nikon light microscope (Nikon).
Masson Trichrome Staining. Paraffin-embedded tumor sections
was deparaffinized and rehydrated. The slides were then stain-
ed using aMasson Trichrome kit (St. Louis, MO) according to the
manufacturer's instructions.
SMA and TUNEL Assay. Paraffin-embedded tumor sections
were sequentially stained with Alexa Fluor 647 for R-SMA
(alpha smooth muscle Actin, Abcam, Cambridge, MA) immuno-
fluorescence staining, and FITC for TUNEL Assay. For immuno-
fluorescence on R-SMA, the slides were deparaffinized through
xylene and a graded alcohol series. After antigen was retrieved
in antigen retrieval buffer (Tris-EDTA buffer, pH 9.0), all of
the sections were blocked by 1% bovine albumin (Sigma,
St. Louis, MO) for 1 h at room temperature before they were
incubated with a primary polycolonal rabbit anti-R-SMA anti-
body (Abcam, Cambridge, MA) at 1:100 dilution overnight at
4 C. Immunocomplexes were visualized with the correspond-
ing Alexa Fluor 647-labeled goat anti rat secondary antibody at
a 1:100 dilution for 1 h at room temperature in the dark. Slides
were then rinsed with PBS, prefixed with 4% formaldehyde.
Apoptosis in situ was then detected by TdT-dependent dUTP-
biotin nick end labeling (TUNEL) assay using apoptosis detec-
tion kit (Promega, Madison,WI) according to themanufacturer's
instructions. Slides were then rinsed with PBS and coverslipped
with Vectashield with DAPI (Vector Laboratories, Burlingame,
CA). All staining was evaluated and digital images were ac-
quired by Eclipse TiU inverted microscope (Nikon Corp.,
Tokyo, Japan)  20 magnification. Five randomly selected
microscopic fields were quantitatively analyzed on ImageJ
(National Institutes of Health).
CD-31 Antibody Staining. In order to observe the vasculature,
the sections were incubated with a 1:250 dilution of CD31
primary antibody (Abcam, Cambridge, MA) at 4 C overnight
followed by incubation with FITC-labeled secondary antibody
(1:200, Santa Cruz, CA) for 1 h at room temperature. The sections
were also stained by DAPI and covered with a coverslip. The
sections were observed using a Nikon light microscope (Nikon
Corp., Tokyo, Japan). Five randomly selected microscopic fields
were quantitatively analyzed on ImageJ (National Institutes of
Health).
Study of NPs' Penetration in Tumor. After tumor therapy experi-
ment was complete, mice were administered with DiI encapsu-
lated in PLGA NP at a dose of 0.1 mg/kg DiI and were sacrificed
24 h postintravenous administration. Tumor was embedded in
paraffin and sectioned. Paraffin-embedded tumor sections
were stained with CD31 primary antibody (Abcam, Cambridge,
MA) at 4 C overnight followed by incubation with FITC-labeled
secondary antibody (1:200, Santa Cruz, CA) for 1 h at room tem-
perature. The sections were also stained by DAPI and covered
with a coverslip. The sections were observed using a Nikon light
microscope (Nikon Corp., Tokyo, Japan).
Statistical Analysis. Quantitative data were expressed as
mean ( SEM. The analysis of variance is completed using a
one-way ANOVA. P < 0.05 was considered statistically significant.
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